Sandoz Group AG

Sandoz Group AG has launched two interchangeable denosumab biosimilars, WYOST and Jubbonti, in the US market, expanding treatment options for millions of patients with osteoporosis and cancer-related skeletal events.

Sandoz has reported Q1 2025 net sales in line with expectations, but its financial ratios, including a price-to-earnings ratio of -24,640, indicate significant deviation from industry norms.

Sandoz Group AG reported strong FY 2024 results, driven by double-digit growth in its biosimilars segment, and expects continued growth in 2025 with mid-single digit net-sales growth and improved profitability.